Identifying and Validating Novel Mechanisms of Radiation Resistance in Rhabdomyosarcoma
- Determine the molecular response/resistance signatures with radiotherapy and standard
chemoradiation treatments using the xenograft model of the Pediatric Preclinical
Testing Program (PPTP).
- Validate these novel pathways/biomarkers by their detection within clinically annotated
patient tumor tissue samples and testing their associations with clinical response,
local control rates, and overall survival rates.
OUTLINE: Archived tissue samples of matched primary-relapsed and non-matched primary are
analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between
alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression
profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired
box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical
staining, and fluorescence in situ hybridization (FISH).
Molecular response/resistance signatures of radiotherapy and standard chemoradiation using Spearman's rho
Christopher E. Pelloski, MD
Ohio State University Comprehensive Cancer Center
United States: Federal Government